At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BDTX Black Diamond Therapeutics, Inc.
Closed 11-25 16:00:00 EST
2.51
-0.03
-1.18%
盘后2.50
-0.01-0.39%
17:53 EST
High2.64
Low2.51
Vol348.57K
Open2.58
D1 Closing2.54
Amplitude5.32%
Mkt Cap142.03M
Tradable Cap99.23M
Total Shares56.59M
T/O893.93K
T/O Rate0.88%
Tradable Shares39.54M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Black Diamond Therapeutics Inc : Stifel Cuts Target Price to $16 From $18
Black Diamond Therapeutic's Cash, Cash Equivalents, And Investments Of $112.7M As Of September 30, 2024; Expected To Be Sufficient To Fund Operations Into Q2 Of 2026
Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.